Historical Valuation
Nektar Therapeutics (NKTR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 21.90 is considered Overvalued compared with the five-year average of -2.86. The fair price of Nektar Therapeutics (NKTR) is between 4.05 to 36.18 according to relative valuation methord. Compared to the current price of 39.71 USD , Nektar Therapeutics is Overvalued By 9.76%.
Relative Value
Fair Zone
4.05-36.18
Current Price：39.71
9.76%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Nektar Therapeutics (NKTR) has a current Price-to-Book (P/B) ratio of 10.03. Compared to its 3-year average P/B ratio of 1.99 , the current P/B ratio is approximately 403.56% higher. Relative to its 5-year average P/B ratio of 2.22, the current P/B ratio is about 352.45% higher. Nektar Therapeutics (NKTR) has a Forward Free Cash Flow (FCF) yield of approximately -21.55%. Compared to its 3-year average FCF yield of -117.52%, the current FCF yield is approximately -81.66% lower. Relative to its 5-year average FCF yield of -83.18% , the current FCF yield is about -74.09% lower.
P/B
Median3y
1.99
Median5y
2.22
FCF Yield
Median3y
-117.52
Median5y
-83.18
Competitors Valuation Multiple
AI Analysis for NKTR
The average P/S ratio for NKTR competitors is 4.66, providing a benchmark for relative valuation. Nektar Therapeutics Corp (NKTR.O) exhibits a P/S ratio of 21.90, which is 369.69% above the industry average. Given its robust revenue growth of -51.13%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for NKTR
1Y
3Y
5Y
Market capitalization of NKTR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NKTR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NKTR currently overvalued or undervalued?
Nektar Therapeutics (NKTR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 21.90 is considered Overvalued compared with the five-year average of -2.86. The fair price of Nektar Therapeutics (NKTR) is between 4.05 to 36.18 according to relative valuation methord. Compared to the current price of 39.71 USD , Nektar Therapeutics is Overvalued By 9.76% .
What is Nektar Therapeutics (NKTR) fair value?
NKTR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Nektar Therapeutics (NKTR) is between 4.05 to 36.18 according to relative valuation methord.
How does NKTR's valuation metrics compare to the industry average?
The average P/S ratio for NKTR's competitors is 4.66, providing a benchmark for relative valuation. Nektar Therapeutics Corp (NKTR) exhibits a P/S ratio of 21.90, which is 369.69% above the industry average. Given its robust revenue growth of -51.13%, this premium appears unsustainable.
What is the current P/B ratio for Nektar Therapeutics (NKTR) as of Jan 11 2026?
As of Jan 11 2026, Nektar Therapeutics (NKTR) has a P/B ratio of 10.03. This indicates that the market values NKTR at 10.03 times its book value.
What is the current FCF Yield for Nektar Therapeutics (NKTR) as of Jan 11 2026?
As of Jan 11 2026, Nektar Therapeutics (NKTR) has a FCF Yield of -21.55%. This means that for every dollar of Nektar Therapeutics’s market capitalization, the company generates -21.55 cents in free cash flow.
What is the current Forward P/E ratio for Nektar Therapeutics (NKTR) as of Jan 11 2026?
As of Jan 11 2026, Nektar Therapeutics (NKTR) has a Forward P/E ratio of -4.58. This means the market is willing to pay $-4.58 for every dollar of Nektar Therapeutics’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Nektar Therapeutics (NKTR) as of Jan 11 2026?
As of Jan 11 2026, Nektar Therapeutics (NKTR) has a Forward P/S ratio of 21.90. This means the market is valuing NKTR at $21.90 for every dollar of expected revenue over the next 12 months.